Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Kalaris Therapeutics reported positive Phase 1a SAD results for TH103 in neovascular AMD, demonstrating robust structural and functional improvements in 17 treatment-naive patients. Pharmacokinetic data indicated 27- to 53-fold lower Cmax compared to current anti-VEGF agents, with 29% of patients requiring no retreatment over six months.
Key figures
- Drug Name
- TH103
- Phase Of Trial
- Phase 1a SAD
- Cmax fold reduction
- 27- to 53-fold
- No retreatment 6mo pct
- 29%
- Retreated 4mo plus pct
- 41%
- Retreated 5mo plus pct
- 35%
- Patients treatment naive
- 17
- Phase 1b 2 data timeline
- 1H 2027
- Patients treatment experienced
- 3
AI analysis
Red flags1 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.